NCT00143663已完成3 期
A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 100 mg Versus Placebo in Subjects With Primary Hypercholesterolemia
Takeda0 个研究点目标入组 361 人开始时间: 2005年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 361
- 主要终点
- Change from Baseline in Low-Density Lipoprotein cholesterol
研究概览
简要总结
The purpose of this study is to determine if patients with elevated cholesterol, but not taking any other lipid medication, could lower their cholesterol with administration of lapaquistat acetate, once daily (QD).
详细描述
This study will evaluate the efficacy and safety of TAK-475 (lapaquistat acetate) compared to placebo in subjects with primary hypercholesterolemia. Subjects who have signed the informed consent will undergo necessary evaluations to determine eligibility for a dietary run-in phase. Subjects who meet randomization criteria will enter treatment with one of the following randomized treatments: lapaquistat acetate or placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female participants of childbearing potential cannot be been pregnant, lactating and are not planning on becoming pregnant and agrees to use acceptable forms of contraception throughout the course of this study.
- •Must have a mean low-density lipoprotein cholesterol values between 3.367 and 5.689 mmol/L, inclusive, from 2 consecutive samples taken at least 1 week apart with the difference between the 2 values not exceeding 15% of the higher value.
- •Must have a triglyceride value of 4.516 mmol/L or less from 2 consecutive samples taken at least 1 week apart with the upper value from either sample being 5.081 mmol/L or less.
- •Has clinical laboratory evaluations within the reference ranges for the testing laboratory unless the results were deemed not clinically significant by the investigator or sponsor.
- •Is willing and able to maintain a standardized low-cholesterol diet.
排除标准
- •Has an alanine aminotransferase or aspartate aminotransferase level greater than 1.5 times the upper limit of normal, active liver disease or jaundice.
- •Has a serum creatinine level greater than 135 μmol/L.
- •Has a creatine phosphokinase value greater than three times the upper limit of normal.
- •Has diabetes mellitus type 1 or
- •Has a history of cancer that had been in remission for less than 5 years prior to the first dose of study drug. This criterion did not include subjects with basal cell or stage I squamous cell carcinoma of the skin.
- •Has an endocrine disorder, such as Cushing syndrome, hyperthyroidism, or inappropriately treated hypothyroidism, affecting lipid metabolism.
- •Has a history of myocardial infarction, angina pectoris, transient ischemic attacks, cerebrovascular accident, peripheral vascular disease, abdominal aortic aneurysm, coronary revascularization or multiple risk factors that present a 10-year risk for CHD of greater than 20%, based on Framingham risk scoring.
- •Has a positive hepatitis B surface antigen or hepatitis C virus antibody, as determined by medical history and/or participant's verbal report.
- •Has a positive human immunodeficiency virus test result or was taking antiretroviral medications, as determined by medical history and/or subject's verbal report.
- •Is unable or unwilling to discontinue excluded medications or to continue stable doses of "stable dose" medications or would require treatment with any excluded medication during the study.
- •Has had exposure to lapaquistat acetate in other studies or was participating or enrolled in another investigational study within the previous 30 days or, for drugs with a long half-life, within a period of less than 5 times the drug's half-life.
- •Has a history or presence of a clinically significant food allergy that would prevent adherence to the therapeutic lifestyle change (or equivalent) diet.
- •Has a known heterozygous or homozygous familial hypercholesterolemia or known type III hyperlipoproteinemia (familial dysbetalipoproteinemia).
- •Has fibromyalgia, myopathy, rhabdomyolysis, or unexplained muscle pain.
- •Has uncontrolled hypertension.
- •Has inflammatory bowel disease or any other malabsorption syndrome or had gastric bypass or any other surgical procedure for weight loss.
- •Has a history of drug abuse or alcohol abuse within the past 2 years.
- •Has any other serious disease or condition at Run-In or at Randomization that might reduce life expectancy, impair successful management according to the protocol, or make the subject an unsuitable candidate to receive study drug.
研究组 & 干预措施
Lapaquistat Acetate 100 mg QD
Experimental
干预措施: Lapaquistat Acetate (Drug)
Placebo QD
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change from Baseline in Low-Density Lipoprotein cholesterol
时间窗: Week 12 or Final Visit
次要结局
- Change from Baseline in Calculated Low-Density Lipoprotein cholesterol(Week 12 or Final Visit)
- Change from Baseline in High-Density Lipoprotein cholesterol(Week 12 or Final Visit)
- Change from Baseline in the ratio of Low-Density Lipoprotein cholesterol/ High-Density Lipoprotein cholesterol(Week 12 or Final Visit)
- Change from Baseline in Very Low-Density Lipoprotein cholesterol(Week 12 or Final Visit)
- Change from Baseline in non- High-Density Lipoprotein cholesterol(Week 12 or Final Visit)
- Change from Baseline in Triglycerides(Week 12 or Final Visit)
- Change from Baseline in Total Cholesterol(Week 12 or Final Visit)
- Change from Baseline in the ratio of Total Cholesterol/High-Density Lipoprotein cholesterol(Week 12 or Final Visit)
- Change from Baseline in apolipoprotein A1(Week 12 or Final Visit)
- Change from Baseline in apolipoprotein B(Week 12 or Final Visit)
- Change from Baseline in the ratio of apolipoprotein B/ apolipoprotein A1(Week 12 or Final Visit)
- Change from Baseline in High-Sensitivity C-reactive Protein(Week 12 or Final Visit)
研究者
相似试验
尚未招募
2 期
Clinical Study To Evaluate Effect of WH5 Gel Vs Povidone Iodine Ointment in Dushta Vrana with special reference to Non-healing WoundCTRI/2020/09/028130Gufic Biosciences Limited
进行中（未招募）
1 期
Effect of testosterone in male patients on regular hemodialysisHypogonadal males undergoing hemodialysis (HD).EUCTR2011-005439-20-SEDept of Renal medicine40
进行中（未招募）
1 期
A double-blind randomized study to determine the effect of empagliflozin versus placebo on brain insulin sensitivity in patients with prediabetesEUCTR2016-003477-18-DEniversity Hospital Tuebingen40
进行中（未招募）
不适用
A randomised, double-blind study to assess the efficacy and safety of prophylactis use of maribavir versus oral ganciclovir for the prevention of cytomegalovirus disease in recipients of orthotopic liver transplants - NDPatient undergone to orthotopic liver transplantsMedDRA version: 9.1Level: LLTClassification code 10011831Term: Cytomegalovirus infectionEUCTR2007-004729-16-ITVIROPHARMA INCORPORATED348
招募中
不适用
Maternal and neonatal effects of remifentanil in women undergoing ceasarean section in relation to multidrug resistance protein 1 (MDR1) and mu-opioid receptor (OPRM) polymorphismspregnant women with hypertension, chronic or gestational, including preeclampsia indicated to caesarean sectionAnaesthesiology - AnaestheticsACTRN12612001165875Interni grantove agentury Ministerstva zdravotnictvi (IGA)160